This year’s conference highlighted a number of critical areas in clinical R&D including financial management, representation, ...

In this video interview, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced Clinical, address ...

Genomics has long been a primary focus in precision medicine, but other areas of research are increasingly being used to help ...

At the current rate of progress, it will take until 2158 to reach full gender parity based on a global measure of opportunity ...

In this video interview, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced Clinical, ...

Phase III REMIX-1 and REMIX-2 trials demonstrated that remibrutinib, an oral BTK inhibitor, significantly reduced chronic ...

Teams must work together with technology solutions and optimize integration to unlock their full potential. Clinical trials ...

In this video interview, Iddo Peleg, CEO and co-founder at Yonalink, highlights the need for a satellite model in bringing ...

In this video interview, Iddo Peleg, CEO and co-founder at Yonalink, discusses the need for change in the clinical research ...

Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...

In this video interview, Iddo Peleg, CEO and co-founder at Yonalink, talks innovation in clinical technology and how the FDA can continue to promote its adoption.

Ron Lanton, Partner, Lanton Law, shares his insights on the legal and political consequences of the NIH funding freeze and potential options for continuing research.